Press release
Hypoparathyroidism Market Forecast 2032: FDA, EMA, PDMA Approvals, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight | TRANSCON PTH (palopegteriparatide), Eneboparatide (AZP-3601)
Hypoparathyroidism Market
(Albany, USA) DelveInsight's "Hypoparathyroidism Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Hypoparathyroidism, historical and forecasted epidemiology as well as the Hypoparathyroidism market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Hypoparathyroidism market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Hypoparathyroidism market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Hypoparathyroidism treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Hypoparathyroidism market.
Request for a Free Sample Report @ Hypoparathyroidism Market Forecast [https://www.delveinsight.com/report-store/hypoparathyroidism-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Some facts of the Hypoparathyroidism Market Report are:
According to DelveInsight, Hypoparathyroidism market size is expected to grow at a decent CAGR by 2032.
Leading Hypoparathyroidism companies working in the market are Ascendis Pharma, Amolyt Pharma, Bridgebio, Calcilytix Therapeutics, Aerami Therapeutics Inc, Aeterna Zentaris Inc, BridgeBio Pharma Inc, Eli Lilly, Entera Bio Ltd, Extend Biosciences, GC Biopharma Corp, MBX Biosciences Inc, ProLynx, Rani Therapeutics and others.
Key Hypoparathyroidism Therapies expected to launch in the market are TRANSCON PTH (palopegteriparatide), Eneboparatide (AZP-3601), Encaleret (BBP-305/CLTX-305), and many others.
On March 2024, Amolyt Pharma announced results of a Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Eneboparatide (AZP-3601), a Parathyroid Hormone Receptor Agonist, in Patients With Chronic Hypoparathyroidism (CALYPSO)
On January 2024, Ascendis Pharma A/S announced results of a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism: PaTHway TRIAL.
On November 2023, Entera Bio Ltd announced results of a Phase 1b, Open-label, Partially Randomised Study to Assess Safety and Compare Pharmacokinetics of New Oral hPTH(1-34) Tablet Formulations vs. Oral EBP05 Tablets and Subcutaneous Forteo Registered Injection in Healthy Male Subjects.
On May 2022, Visen Pharmaceuticals (Shanghai) Co., Ltd. announced results of a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism: PaTHway CHINA TRIAL
Hypoparathyroidism Overview
Hypoparathyroidism is a rare endocrine disorder characterized by insufficient production or action of parathyroid hormone (PTH), leading to low levels of calcium in the blood and high levels of phosphate. This imbalance disrupts the body's calcium regulation, causing symptoms such as muscle cramps, tingling sensations, seizures, and mood disturbances. The most common cause is damage to or removal of the parathyroid glands during thyroid surgery, although autoimmune conditions and genetic factors can also contribute. Diagnosis typically involves blood tests to measure calcium, phosphate, and PTH levels. Treatment aims to restore calcium balance and prevent complications. This often involves supplementation with calcium and active vitamin D analogs to increase calcium absorption from the gut and reduce phosphate levels. Regular monitoring of calcium and vitamin D levels is essential to adjust treatment and prevent complications such as kidney stones, osteoporosis, and calcifications in the brain. Despite available treatments, managing hypoparathyroidism can be challenging, requiring ongoing medical care and support to maintain optimal calcium levels and quality of life.
Do you know what will be the Hypoparathyroidism market share in 7MM by 2032 @ https://www.delveinsight.com/sample-request/hypoparathyroidism-market [https://www.delveinsight.com/sample-request/hypoparathyroidism-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Hypoparathyroidism Market
The Hypoparathyroidism market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Hypoparathyroidism market trends by analyzing the impact of current Hypoparathyroidism therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Hypoparathyroidism market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Hypoparathyroidism market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Hypoparathyroidism market in 7MM is expected to witness a major change in the study period 2019-2032.
Hypoparathyroidism Epidemiology
The Hypoparathyroidism epidemiology section provides insights into the historical and current Hypoparathyroidism patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Hypoparathyroidism market report also provides the diagnosed patient pool, trends, and assumptions.
Interested to know how the emerging diagnostic approaches will be contributing in increased Hypoparathyroidism diagnosed prevalence pool? Download report @ https://www.delveinsight.com/sample-request/hypoparathyroidism-market [https://www.delveinsight.com/sample-request/hypoparathyroidism-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Hypoparathyroidism Drugs Uptake
This section focuses on the uptake rate of the potential Hypoparathyroidism drugs recently launched in the Hypoparathyroidism market or expected to be launched in 2019-2032. The analysis covers the Hypoparathyroidism market uptake by drugs, patient uptake by therapies, and sales of each drug.
Hypoparathyroidism Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Hypoparathyroidism market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Hypoparathyroidism Pipeline Development Activities
The Hypoparathyroidism report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Hypoparathyroidism key players involved in developing targeted therapeutics.
Download report to know which TOP 3 therapies will be capturing the largest Hypoparathyroidism market share by 2032? Click here @ https://www.delveinsight.com/sample-request/hypoparathyroidism-market [https://www.delveinsight.com/sample-request/hypoparathyroidism-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Hypoparathyroidism Therapeutics Assessment
Major key companies are working proactively in the Hypoparathyroidism Therapeutics market to develop novel therapies which will drive the Hypoparathyroidism treatment markets in the upcoming years are Ascendis Pharma, Amolyt Pharma, Bridgebio, Calcilytix Therapeutics, Aerami Therapeutics Inc, Aeterna Zentaris Inc, BridgeBio Pharma Inc, Eli Lilly, Entera Bio Ltd, Extend Biosciences, GC Biopharma Corp, MBX Biosciences Inc, ProLynx, Rani Therapeutics and others.
Do you know how TRANSCON PTH and Eneboparatide market launch will be impacting the Hypoparathyroidism market CAGR? Download sample report @ https://www.delveinsight.com/sample-request/hypoparathyroidism-market [https://www.delveinsight.com/sample-request/hypoparathyroidism-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Hypoparathyroidism Report Key Insights
1. Hypoparathyroidism Patient Population
2. Hypoparathyroidism Market Size and Trends
3. Key Cross Competition in the Hypoparathyroidism Market
4. Hypoparathyroidism Market Dynamics (Key Drivers and Barriers)
5. Hypoparathyroidism Market Opportunities
6. Hypoparathyroidism Therapeutic Approaches
7. Hypoparathyroidism Pipeline Analysis
8. Hypoparathyroidism Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Hypoparathyroidism Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Hypoparathyroidism Competitive Intelligence Analysis
4. Hypoparathyroidism Market Overview at a Glance
5. Hypoparathyroidism Disease Background and Overview
6. Hypoparathyroidism Patient Journey
7. Hypoparathyroidism Epidemiology and Patient Population
8. Hypoparathyroidism Treatment Algorithm, Current Treatment, and Medical Practices
9. Hypoparathyroidism Unmet Needs
10. Key Endpoints of Hypoparathyroidism Treatment
11. Hypoparathyroidism Marketed Products
12. Hypoparathyroidism Emerging Therapies
13. Hypoparathyroidism Seven Major Market Analysis
14. Attribute Analysis
15. Hypoparathyroidism Market Outlook (7 major markets)
16. Hypoparathyroidism Access and Reimbursement Overview
17. KOL Views on the Hypoparathyroidism Market
18. Hypoparathyroidism Market Drivers
19. Hypoparathyroidism Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Hypoparathyroidism Market Forecast 2032: FDA, EMA, PDMA Approvals, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight | TRANSCON PTH (palopegteriparatide), Eneboparatide (AZP-3601), Encaleret (BBP-305/CLTX-305), more
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hypoparathyroidism-market-forecast-2032-fda-ema-pdma-approvals-clinical-trials-epidemiology-therapies-and-companies-by-delveinsight-transcon-pth-palopegteriparatide-eneboparatide-azp3601]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hypoparathyroidism Market Forecast 2032: FDA, EMA, PDMA Approvals, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight | TRANSCON PTH (palopegteriparatide), Eneboparatide (AZP-3601) here
News-ID: 3482802 • Views: …
More Releases from ABNewswire
AKU Woodpanel Leads 2026 Ranking of Wood Acoustic Panel Suppliers
AKU Woodpanel tops a 2026 list of seven wood acoustic panel suppliers for offices, ranked on veneer options, acoustic construction, and commercial fire-retardant fit.
NEW YORK - August 20, 2026 - AKU Woodpanel [https://akuwoodpanel.com/], a manufacturer and supplier of decorative and acoustic wood wall panels for residential and commercial projects, today released its ranking of the seven wood acoustic panel suppliers shaping office and commercial interior noise control in 2026 -…
Shopr Rewards Brings Immediate Cash Back and Future Travel Savings Together on E …
Eligible users can now earn two forms of value from the same qualifying purchase at more than 300 participating brands
Orlando, Fla. - August 20, 2026 - Shopr Rewards, LLC ("Shopr" or the "Company"), a fintech-powered engagement and loyalty platform, today announced an enhancement to its rewards experience that allows eligible users to earn both Instant Cash Back and Travel Credits from the same qualifying purchase.
When an eligible user makes a…
Award-Winning Educator Jacqueline H. Faber Introduces Newly Republished Editions …
Image: https://www.abnewswire.com/upload/2026/08/f96a33d439f234f038d685aa65ce8721.jpg
California, USA - August 20, 2026 - After spending 37 years helping children discover the joy of learning, award-winning educator and author Jacqueline H. Faber (Jacquie Faber) is beginning an exciting new chapter in her literary journey. Her imaginative children's stories are reaching readers in newly republished editions under her own publishing imprints. This gives Faber greater creative ownership over the books that carry her signature combination of storytelling,…
No-Dig Sewer Repair Explained: Why New Orleans Homeowners Are Skipping the Excav …
Pelican Underground, a licensed, insured, and bonded New Orleans-area trenchless specialist, explains how no-dig sewer repair - CIPP lining and pipe bursting - rebuilds failing sewer lines in a single day without excavating yards, driveways, or historic property.
NEW ORLEANS, LA - August 20, 2026 - No-dig sewer repair, also called trenchless repair - is changing how New Orleans homeowners fix failing sewer lines. Instead of digging a trench across a…
More Releases for Hypoparathyroidism
Market Trend Insights: The Impact of Recent Advances on the Hypoparathyroidism M …
The hypoparathyroidism market is positioned for notable expansion over the coming years, driven by advancements in medical treatments and improved healthcare practices. This sector is becoming increasingly important as new technologies and therapies emerge to address the challenges faced by patients with this rare endocrine disorder. Let's explore the market's projected size, key players, growth trends, and segmentation details.
Expected Market Size and Growth Outlook for Hypoparathyroidism
The hypoparathyroidism market is…
Hypoparathyroidism Market to Reach USD 2.06 Billion by 2034
Pune, India - December 2025 - The global Hypoparathyroidism Market, valued at USD 1.21 billion in 2024, is projected to reach USD 2.06 billion by 2034, growing at a 5.5% CAGR (2025-2034), according to Exactitude Consultancy. Increasing incidence of post-thyroidectomy hypoparathyroidism, improved diagnosis of chronic hypocalcemia, and expanding use of recombinant parathyroid hormone (PTH) therapies are key market growth drivers.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71995
Market Summary
The…
Hypoparathyroidism Market Size, Development, Key Opportunity, Application & Fore …
The global hypoparathyroidism market was valued at approximately $1.3 billion in 2023 and is projected to reach around $2.5 billion by 2031. This represents a compound annual growth rate (CAGR) of about 8.8%.
Request a Free Sample Copy@ https://www.datalibraryresearch.com/sample-request/hypoparathyroidism-market-5438
With market research reports garnering immense significance in the speedily transforming market place, the team at Data Library Research endows with Hypoparathyroidism Market report in a way which is predicted. It comprehensively…
Hypoparathyroidism Drug Market: An Overview
Hypoparathyroidism is a rare endocrine disorder characterized by insufficient production of parathyroid hormone (PTH), leading to low calcium levels in the blood. This deficiency causes various complications, including muscle cramps, fatigue, and neurological issues. Managing hypoparathyroidism primarily involves calcium and vitamin D supplements, but newer treatments targeting PTH replacement therapy have emerged, providing more effective and sustainable solutions.
The development of hypoparathyroidism drugs represents a promising area of growth in the…
Hypoparathyroidism Drug Market Size, Share, Trends, Growth and Competitive Analy …
Hypoparathyroidism Drug Market business report provides a profound overview of product specification, technology, product type and production analysis considering major factors such as revenue, cost, and gross margin. The data and information collected to generate this top-notch market report has been derived from the trusted sources such as company websites, white papers, journals, and mergers etc. Hypoparathyroidism Drug Market report includes basic, secondary and advanced information related to the global…
Hypoparathyroidism Treatment Market Size 2024 to 2031.
Market Overview and Report Coverage
Hypoparathyroidism is a rare condition where the parathyroid glands in the neck produce too little parathyroid hormone, resulting in low calcium levels in the blood. The primary treatment for hypoparathyroidism involves calcium and vitamin D supplementation, as well as hormonal therapy.
The future outlook for the Hypoparathyroidism Treatment Market is promising, with a projected growth rate of 20.00% during the forecasted period. This growth can…
